Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
Department of Biomolecular Science, University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
Cells. 2022 Dec 16;11(24):4101. doi: 10.3390/cells11244101.
Kallikrein-related peptidase (KLK)6 is associated with inflammatory diseases and neoplastic progression. KLK6 is aberrantly expressed in several solid tumors and regulates cancer development, metastatic progression, and drug resistance. However, the function of KLK6 in the tumor microenvironment remains unclear. This study aimed to determine the role of KLK6 in the tumor microenvironment. Here, we uncovered the mechanism underlying KLK6-mediated cross-talk between cancer cells and macrophages. Compared with wild-type mice, KLK6-/- mice showed less tumor growth and metastasis in the B16F10 melanoma and Lewis lung carcinoma (LLC) xenograft model. Mechanistically, KLK6 promoted the secretion of tumor necrosis factor-alpha (TNF-α) from macrophages via the activation of protease-activated receptor-1 (PAR1) in an autocrine manner. TNF-α secreted from macrophages induced the release of the C-X-C motif chemokine ligand 1 (CXCL1) from melanoma and lung carcinoma cells in a paracrine manner. The introduction of recombinant KLK6 protein in KLK6-/- mice rescued the production of TNF-α and CXCL1, tumor growth, and metastasis. Inhibition of PAR1 activity suppressed these malignant phenotypes rescued by rKLK6 in vitro and in vivo. Our findings suggest that KLK6 functions as an important molecular link between macrophages and cancer cells during malignant progression, thereby providing opportunities for therapeutic intervention.
激肽释放酶相关肽酶 6(KLK6)与炎症性疾病和肿瘤进展有关。KLK6 在几种实体瘤中异常表达,调节癌症发展、转移进展和耐药性。然而,KLK6 在肿瘤微环境中的功能尚不清楚。本研究旨在确定 KLK6 在肿瘤微环境中的作用。在这里,我们揭示了 KLK6 介导的癌细胞与巨噬细胞之间串扰的机制。与野生型小鼠相比,KLK6-/- 小鼠在 B16F10 黑色素瘤和 Lewis 肺癌(LLC)异种移植模型中的肿瘤生长和转移减少。机制上,KLK6 通过自分泌方式激活蛋白酶激活受体 1(PAR1)促进巨噬细胞中肿瘤坏死因子-α(TNF-α)的分泌。巨噬细胞分泌的 TNF-α以旁分泌方式诱导黑色素瘤和肺癌细胞释放 C-X-C 基序趋化因子配体 1(CXCL1)。在 KLK6-/- 小鼠中引入重组 KLK6 蛋白可挽救 TNF-α和 CXCL1 的产生、肿瘤生长和转移。PAR1 活性的抑制可抑制 rKLK6 在体外和体内挽救的这些恶性表型。我们的研究结果表明,KLK6 在恶性进展过程中作为巨噬细胞和癌细胞之间的重要分子联系,从而为治疗干预提供了机会。